Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Anavex Reports ANAVEX 2-73 Results in Preclinical Model of Alzheimer’s Disease

Published: Monday, November 04, 2013
Last Updated: Monday, November 04, 2013
Bookmark and Share
ANAVEX 2-73 dose-dependently blocks Tau and amyloid-beta (“amyloid”) proteins and memory deficit in a mouse model of Alzheimer’s disease (AD).

A reduction in these two main hallmarks of Alzheimer’s has the potential to stop, slow or reverse the disease.  The report also suggests that, because it is targeting the mixed muscarinic and Sigma-1 receptors, ANAVEX 2-73 is able to achieve its effect further “upstream” in the Alzheimer’s disease cascade.  This compares to most other current AD clinical development compounds that are mainly downstream and single-targeted approaches, which might be limited by adverse effects.  More interestingly, the mixed muscarinic and Sigma-1 agonist ANAVEX 2-73 exhibited powerful effects despite its moderate affinity for these receptors, emphasizing its great advantage for potential therapy in Alzheimer’s disease.

Tangui Maurice, PhD, CNRS Research Director, Head of Team 2 ‘Endogenous Neuroprotection in Neurodegenerative Diseases’, at the University of Montpellier and INSERM, and one of the study authors, said, “ANAVEX 2-73 also dose-dependently reduced C99 levels in the hippocampus, an effect which researchers are currently trying to achieve with BACE inhibitors.  In the mouse model we also confirmed the central role of the kinase GSK-3 beta in Alzheimer’s disease toxicity through drugs acting either directly as GSK-3 beta inhibitors, or indirectly, as mixed muscarinic and Sigma-1 ligands. Both can efficiently alleviate these two major alterations observed in the Alzheimer’s animal model, as well as in Alzheimer’s patient brains. However, by targeting GSK-3 beta indirectly as ANAVEX 2-73 does through muscarinic and Sigma-1 ligands, we could avoid the toxicity seen by directly targeting GSK-3 beta.”

Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, said, “Using further upstream targets that efficiently block tau phosphorylation and amyloid overproduction might be a more comprehensive approach in successfully treating this complex disease. Together with previously confirmed findings demonstrating the ability of ANAVEX 2-73 to reduce mitochondrial oxidative stress, this publication strengthens the case for a potential pharmacological treatment for Alzheimer’s disease.”

The report, entitled “Blockade of Tau Hyperphosphorylation and Amyloid-beta1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and Sigma-1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease,” is based on a scientific study conducted in France at the University of Montpellier and INSERM.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos